SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

January 12, 2005
Date of Report
(Date of Earliest Event Reported)

 
SONOSITE, INC.
(Exact Name of Registrant as Specified in Charter)
 

 

21919 30th Drive S.E., Bothell, Washington 98021-3904
(Address of Principal Executive Offices)   (Zip Code)

(425) 951-1200
(Registrant's Telephone Number, Including Area Code)

None
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e4(c))

 

Item 8.01	Other Events.
On January 12, 2005, SonoSite, Inc. (the "Company") received 510(k) clearance from the U.S. Food and Drug Administration for its third generation ultrasound technology.  As previously disclosed, the Company plans to launch and begin shipping products incorporating this technology for selected clinical markets by mid-year 2005.

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, SonoSite, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						SONOSITE, INC.
Dated:		January 24, 2005				By:		/s/   MICHAEL J. SCHUH
								Michael J. Schuh Chief Financial Officer